Magenta Therapeutics buy nvestor
Start price
08.01.22
/
50%
€4.08
Target price
08.01.23
€6.00
Performance (%)
-26.40%
End price
22.01.22
€3.01
Summary
This prediction ended on 22.01.22 with a price of €3.01. The price of Magenta Therapeutics has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.40%. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Magenta Therapeutics | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
According to nvestor what are the pros and cons of Magenta Therapeutics for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Valuable balance sheet
Standard Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Capable Management
Good culture
Innovative
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Known brand
Future proof or reliable business model
Cons
Comments by nvestor for this prediction
In the thread Magenta Therapeutics diskutieren
Buy mit Kursziel 6,0
In the thread Trading Magenta Therapeutics
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.